HIV prevention news: Europe

From 2012 to 2016, NAM published a monthly bulletin that covered HIV prevention news and research in Europe, and of relevance to Europe. It aimed to strengthen knowledge of new prevention options and share the latest HIV prevention news and research.

In that period, HIV prevention evolved rapidly, with landmark research developments in new prevention technologies and approaches, including HIV treatment as prevention (TasP), pre-exposure prophylaxis (PrEP), expanded testing programmes and advocacy for proven approaches that remain unprovided, such as syringe and needle exchange and condoms in prisons.

An archive of the bulletin is available in English, Spanish, Portuguese, French and Russian.


Issue #38 - August 2016

  • AIDS 2016 special
  • Still no transmissions seen from people with an undetectable viral load in PARTNER study
  • Vaccine comfortably out-performs previous effective candidate
  • Mixed results for treatment-as-prevention trials
  • US now has at least 80,000 on PrEP: first thousand on French programme
  • Studies look at PrEP in black and young gay men
  • Other recent news headlines
  • Editors' picks from other sources
  • Make your voice heard on PrEP in the UK
  • HIV prevention bulletin
  • Acknowledgements

Issue #37 - June 2016

  • Denmark has first evidence of treatment as prevention working in gay men in a high-income country
  • Cost is biggest barrier to PrEP in Europe, ECDC report declares
  • Opt-out HIV testing in a hospital emergency department may cost less than managing two patients with undiagnosed HIV
  • Which men stand to benefit most from access to PrEP?
  • Risk of sexual transmission of HIV may persist during first six months of ART
  • American gay men’s use of condoms has been falling for a decade, regardless of serosorting or PrEP
  • Other recent news headlines
  • Editors' picks from other sources
  • PrEP legal challenge
  • The Flash! PrEP in Europe survey
  • The PrEP in the Wild survey
  • HIV prevention bulletin
  • Acknowledgements

Issue #36 - May 2016

  • England’s PrEP policy in disarray after NHS U-turn
  • Kidney function decline in people taking Truvada PrEP supports need for monitoring
  • Long-acting PrEP injection tolerable for male volunteers, but dose adjustment needed
  • ‘On-demand’ rectal microbicide gel reasonably acceptable – daily less so
  • Two-thirds of gay men in US have heard of PrEP but only 1 in 20 has used it
  • Many factors associated with irregular attendance at London HIV clinics
  • Simple outreach on dating websites increases HIV testing rate
  • Other recent news headlines
  • Editors' picks from other sources
  • HIV prevention bulletin
  • Acknowledgements

Issue #35 - March 2016

  • Conference special
  • French PrEP trial: half only used PrEP, a quarter condoms and PrEP, one in six neither
  • High levels of chemsex and injecting in HIV-positive gay men in English clinics
  • Almost-certain case of PrEP failure due to drug resistance reported
  • People with HIV considerably overestimate their chance of infecting someone
  • Major disparities persist in lifetime risk of HIV diagnosis in the US
  • Expanding treatment and PrEP could prevent 185,000 new HIV infections, US CDC says
  • Vaginal rings moderately effective – but not in the youngest women
  • Other recent news headlines
  • Editors' picks from other sources
  • HIV prevention bulletin
  • Acknowledgements

Issue #34 - February 2016

  • Tenofovir resistance may develop in more than half of patients failing HIV treatment in sub-Saharan Africa
  • New PrEP studies will be a challenge, statisticians warn
  • Model suggests HIV vaccine still has key role in ending AIDS
  • UK and Dutch studies show that PrEP is the most powerful single HIV prevention method we currently have
  • English sexual health clinics have started to support people buying PrEP online
  • Two HIV infections on solo tenofovir pose significant research questions
  • Lessons learnt from the history of contraception are relevant for the implementation of PrEP
  • Other recent news headlines
  • Editors' picks from other sources
  • HIV prevention bulletin
  • Acknowledgements

Issue #33 - January 2016

  • France approves PrEP: so do South Africa and Kenya
  • HIV diagnoses continue to increase in gay men across Europe, and in heterosexuals in the east
  • US reports falls in new HIV infections in most populations
  • PrEP programmes continue to report zero HIV infections in the US
  • HIV drug resistance acquired on PrEP fades rapidly
  • Australian study shows that gay men have many types of sexual relationship and classic monogamy is uncommon
  • Barcelona study predicts who will need PrEP
  • For African migrants in France, destitution shapes sexual behaviour and HIV risk
  • Other recent news headlines
  • Editors' picks from other sources
  • European HIV Test Finder
  • HIV prevention bulletin
  • Acknowledgements

This project has been supported via a grant from Gilead Sciences Europe Ltd, Merck & Co., Inc. and ViiV Healthcare.

Gilead Sciences Europe Ltd, Merck & Co., Inc. and ViiV Healthcare have provided funding for this project and have had no editorial control over the content of the materials.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.